News
QDEL
45.53
-2.72%
-1.28
QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference
Members of QuidelOrtho's management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024. The conference will be held in Orlando, FL. The company is a global provider of innovative in vitro diagnostic technologies for point-of-care and clinical labs.
Barchart · 2d ago
Weekly Report: what happened at QDEL last week (0219-0223)?
Weekly Report · 2d ago
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
Glancy Prongay & Murray LLP has commenced an investigation on behalf of QuidelOrtho Corporation investors concerning the Company’s possible violations of the federal securities laws. On February 21, 2024, the Company terminated the President and Chief Executive Officer of the Company.
Barchart · 6d ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of QuidelOrtho Corporation investors concerning the Company’s possible violations of federal securities laws. On February 21, 2024, Quidel ortho announced that it terminated the Company's President and Chief Executive Officer.
Barchart · 02/21 19:36
The Law Offices of Frank R. Cruz Announces Investigation of QuidelOrtho Corporation (QDEL) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of QuidelOrtho Corporation on behalf of investors. The Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. The company terminated the President and Chief Executive Officer on February 21, 2024.
Barchart · 02/21 17:02
QuidelOrtho may be takeover, activist target with CEO exit, share slump - analyst
QuidelOrtho Corp. May be a takeover target or candidate for an activist investor. The diagnostics company terminated its CEO Douglas Bryant on Wednesday. Bryant's exit comes after Quidel shares plunged 32% a week ago. The company fell short of expectations with its Q4 2023 financials.
Seeking Alpha · 02/21 15:59
QuidelOrtho Fires CEO, Postpones Investor Day After Disappointing Results
QuidelOrtho postponing an investor day. Douglas Bryant, president and CEO of the company, is also resigning from the board of directors. The company posted fourth-quarter results that disappointed both on the top and bottom line. The stock fell 32% on Feb. 14.
Barron‘s · 02/21 14:10
Craig-Hallum downgrades QuidelOrtho (QDEL) to a Hold
TipRanks · 02/21 13:46
QuidelOrtho lets go off CEO Douglas Bryant
Healthcare QuidelOrtho lets go off CEO Douglas Bryant Feb. 21, 2024. Board of Directors has terminated Douglas Bryant, President and CEO of the company. Michael Iskra has been appointed as the Interim CEO, and Robert Bujarski as the interim president.
Seeking Alpha · 02/21 13:08
QuidelOrtho Terminates CEO Douglas Bryant, Michael Iskra Named Interim Replacement
NASDAQ · 02/21 13:07
QuidelOrtho Announces Executive Leadership Restructuring
QuidelOrtho Corporation is undergoing significant leadership changes. Douglas Bryant has been terminated from his roles as President and CEO of the company. His departure is not due to any disputes or disagreements. The Board has appointed an interim CEO and president to lead the company temporarily.
TipRanks · 02/21 12:45
More
Webull provides a variety of real-time QDEL stock news. You can receive the latest news about Quidel through multiple platforms. This information may help you make smarter investment decisions.
About QDEL
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.